ArticleWorld journal of gastroenterology2021
Huanglian decoction suppresses the growth of hepatocellular carcinoma cells by reducing
Article in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- How Traditional Chinese Medicine Works: Biological Mechanisms and Clinical Evidence for Hepatocellular Carcinoma Treatment.Drug design, development and therapy · 2026Review
- Article
- 23-hydroxybetulinic acid induces cell cycle arrest in esophageal cancer cells via the BUB1/STAT3 signaling pathway.Frontiers in oncology · 2026Article
- Dual inhibition of FAS and HAS2/3 by 4-MU in Realgar-Coptis chinensis unveils a metabolic checkpoint for liver cancer therapy.Natural products and bioprospecting · 2025Article
- In Silico Network Toxicology, Molecular Docking, and Multi-Level Bioinformatics Reveal Methyl Eugenol-Induced Hepatocellular Carcinoma Mechanisms in Humans.Cancer medicine · 2025Article
- Identification of CCNB1 as a biomarker for cellular senescence in hepatocellular carcinoma: a bioinformatics and experimental validation study.Discover oncology · 2025Article
- ESCO2 promotes the proliferation of hepatocellular carcinoma through the PI3K/AKT/ mTOR signaling pathway.Journal of Cancer · 2025Article
- An Insight into Research Advances on Herbal and Phytochemical Approaches to the Management of Hepatocellular Carcinoma from January 2020 to July 2024.Anti-cancer agents in medicinal chemistry · 2025Review
- Phloretin attenuates inflammation induced by subarachnoid hemorrhage through regulation of the TLR2/MyD88/NF-kB pathway.Scientific reports · 2024Article
- Baitouweng decoction suppresses growth of esophageal carcinoma cells through miR-495-3p/BUB1/STAT3 axis.World journal of gastrointestinal oncology · 2024Article
- Identification and functional analysis of lactic acid metabolism-related differentially expressed genes in hepatocellular carcinoma.Frontiers in genetics · 2024Article
- CCNB1 is a novel prognostic biomarker and promotes proliferation, migration and invasion in Wilms tumor.BMC medical genomics · 2023Article
- P53 status, and G2/M cell cycle arrest, are determining factors in cell-death induction mediated by ELF-EMF in glioblastoma.Scientific reports · 2023Article
- METTL3 promotes drug resistance to oxaliplatin in gastric cancer cells through DNA repair pathway.Frontiers in pharmacology · 2023Article
- Cyclin B1 expression as an independent prognostic factor for lung adenocarcinoma and its potential pathways.Oncology letters · 2022Article
- Article
- Review
- Integrated Analysis of the Expression Characteristics, Prognostic Value, and Immune Characteristics of PPARG in Breast Cancer.Frontiers in genetics · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the most prevalent cancers in human populations worldwide. Huanglian decoction is one of the most important Chinese medicine formulas, with the potential to treat cancer.
aimTo investigate the role and mechanism of Huanglian decoction on HCC cells.
methodsTo identify differentially expressed genes (DEGs), we downloaded gene expression profile data from The Cancer Genome Atlas Liver Hepatocellular Carcinoma and Gene Expression Omnibus (GSE45436) databases. We obtained phytochemicals of the four herbs of Huanglian decoction from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. We also established a regulatory network of DEGs and drug target genes and subsequently analyzed key genes using bioinformatics approaches. Furthermore, we conducted
resultsBased on the results of the network pharmacological analysis, we revealed 5 bioactive compounds in Huanglian decoction that act on HCC. In addition, a protein-protein interaction network analysis of the target genes of these five compounds as well as expression and prognosis analyses were performed in tumors.
conclusionHuanglian decoction has a significant inhibitory effect on HCC cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.